France· FR:60427957
LITAK 2 mg/ml, solution injectable
A medicinal product containing cladribine, registered in France by LIPOMED (ALLEMAGNE), on the national reimbursement list.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CLADRIBINE
- Manufacturer
- LIPOMED (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- Yes
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
2 priced- cip1334009364066811 flacon(s) en verre de 5 mlEUR 378.95
- cip1334009364067425 flacon(s) en verre de 5 mlEUR 1.64
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Cladribine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsLeustatin 2 mg/ml oplossing voor injectieAtnahs Pharma Netherlands B.V.
- IrelandLitak 2 mg/ml solution for injectionLipomed GmbH
- CzechiaLEUJECTAtnahs Pharma Netherlands B.V., Amsterdam
- United StatesCladribineGenvion Corporation
- FinlandLeujectAtnahs Pharma Netherlands B.V.
- SpainLEUSTATIN 1 MG/ML SOLUCION PARA PERFUSIONAtnahs Pharma Netherlands Bv.
- SwitzerlandLitak 10, Injektions- / InfusionslösungLipomed AG
- PolandBiodribinSieć Badawcza Łukasiewicz – Instytut Chemii Przemysłowej im. Prof. I. Mościckiego
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Leuject
- Belgium · Leustatin
- Bulgaria · Леуджект
- Czechia · Leuject
- Germany · Leustatin
- Spain · Leustatin
- Finland · Leuject
- United Kingdom (Northern Ireland) · Cladribine Zentiva, Leustat
- Greece · Leustatin
- Croatia · Leuject
- Hungary · Leuject
- Iceland · Mavenclad
- Italy · Leustatin
- Liechtenstein · Mavenclad
- Luxembourg · Leustatin
- Netherlands · Leustatin
- Norway · Leuject, Mavenclad
- Poland · Biodribin, Leuject
- Portugal · Cladribina Generis, Leustatin
- Romania · Leuject
- Sweden · Leuject
- Slovenia · Leuject
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4a39ae29-1cbf-4b95-a367-ba55c06c9528 GET /v1/drugs/4a39ae29-1cbf-4b95-a367-ba55c06c9528?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "60427957",
"date_amm": "2004-04-14",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/04/275",
"substance": "CLADRIBINE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about cladribine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.